Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
about
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerLiquid biopsies: genotyping circulating tumor DNATumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesDISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m MutationDetection of circulating tumor DNA in early- and late-stage human malignanciesLiquid biopsy genotyping in lung cancer: ready for clinical utility?Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.The quest to overcome resistance to EGFR-targeted therapies in cancer.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAQuantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide arrayMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularLOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Enhanced ratio of signals enables digital mutation scanning for rare allele detection.BEAMing sheds light on drug resistance.T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsDetection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer.EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysisComparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusA prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations
P2860
Q26775376-B3B0B730-F6C9-4E8F-913A-193B6CA30A13Q26801357-17736171-6E56-41C7-A16E-72B9333F11F7Q26828860-24CF0199-CC99-448D-B8D4-35D8C9E5A51DQ26865779-BA5FDB28-429D-4E5D-AB4F-58976FDF4928Q27010159-FF041792-6BE9-45FF-BB10-1C74CDF18337Q27014117-1EAF1324-9EF4-48CF-B2B3-9957EBE1A9BDQ28076191-6AE5CEB2-09D7-43D0-A711-0D2C3C967EBDQ28082499-53BB6652-94D4-4EB1-9CF8-32550170BCF6Q28087366-1DF1DEF4-DA5B-42B8-B5A1-651FB58087F0Q28394310-67AC94A8-5134-4166-9B27-537C9DCD8177Q28534155-6527786E-FFD4-49B3-AF23-F19B16F3E51FQ29615778-ECDA3126-5F3A-499D-9098-CA51ED923F32Q33567037-CAA750A8-FAD6-45D4-9D62-F5273B4E177DQ33567383-1D881998-F242-4C6E-84D1-154620F2D31EQ33590850-4BA0B4B8-C50B-43EB-ADF7-018E3F95938CQ33725976-737F0182-817A-4D7E-9EDC-28980900C7F2Q33737740-9C0FD75D-A90E-48CE-AB3C-D95B630C56DAQ34158755-6E7E6A5A-B85C-4866-A233-4EB50B9FA183Q34159011-349D43AB-1C75-49BE-B2CF-B016D21019D8Q34360216-8D666871-B962-4883-8511-E9116DF3A514Q34497467-EF397408-45B6-4577-AC45-C83B960B2BCBQ34535332-71181C5E-AE20-4462-95AE-D4A26264829DQ34634536-4E781FB0-31A6-4FAC-8677-7D21B56D2E2EQ34694358-657ABC80-0AFF-48F4-A4D3-A2383AF7175CQ35196345-5E977DC3-1C39-4996-8BBB-811AB69FAC09Q35469393-06C27CB3-DC58-4111-B5D4-BB7C93CBA56BQ35543098-4778AA6D-DFAA-4B5D-A84F-DD6216E3843CQ35627025-C0E199E2-0D49-414F-B66A-B19EB7FB41A6Q35667787-7ACFF762-B82E-419D-B087-B07480907BD4Q35764712-863CAC3D-4EE3-4DE3-A4E5-B40271A6BAD0Q35787132-8261E2AB-2384-4013-87CE-75C7B24686E8Q36095650-D8F938D1-3A0A-4A31-A39B-095A8421D2D6Q36215079-8A9FE897-BF1E-4139-9414-1C3A1120386BQ36278010-FB4DC893-DCD2-47CB-A1D0-AF3F0DB32703Q36282366-A80F131E-ACC9-443B-8CCE-795C3D36A9CDQ36375343-ED74ED0C-CE36-4556-9348-A2320D5B63B9Q36384490-D69B5CCA-751D-452A-929F-CDD9A6916AD4Q36544438-D4A2533F-0884-4D38-9221-9D15D140CD9BQ36574146-2F32DBAE-B8C8-410F-8993-49B402683768Q36580836-0FCA42E1-FA8B-4021-AE4D-9795AC30BA60
P2860
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@en
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@nl
type
label
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@en
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@nl
prefLabel
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@en
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@nl
P2093
P2860
P1476
Noninvasive detection of EGFR ...... nt non-small cell lung cancer.
@en
P2093
Andrew Rogers
Beow Y Yeap
Kristi Vetrand
Lilin Wang
Mike Makrigiorgos
Robert J Distel
Sara Thiede
Yanan Kuang
P2860
P304
P356
10.1158/1078-0432.CCR-08-2592
P407
P50
P577
2009-04-07T00:00:00Z